Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ali Tavakoli Pirzaman MD"'
Autor:
Ali Tavakoli Pirzaman MD, Ali Alishah MS, Bahareh Babajani MS, Pouyan Ebrahimi MD, Seyyed Ali Sheikhi MS, Farhad Moosaei MS, Amirhossein Salarfar MS, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 23 (2024)
Globally, hepatic cancer ranks fourth in terms of cancer-related mortality and is the sixth most frequent kind of cancer. Around 80% of liver cancers are hepatocellular carcinomas (HCC), which are the leading cause of cancer death. It is well known t
Externí odkaz:
https://doaj.org/article/231a6e19dba142b2b22bf5c81a5af289
Autor:
Ali Tavakoli Pirzaman MD, Manijeh Ebrahimzadeh Pirshahid MD, Bahareh Babajani MS, Amirhossein Rahmati MS, Shokat Niknezhad MS, Rezvan Hosseinzadeh MD, Mehdi Taheri MS, Faezeh Ebrahimi-Zadeh MD, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with anticancer effects. Oxaliplatin has a role in the treatment of several cancers. It is one of the few drugs which can eliminate the neoplast
Externí odkaz:
https://doaj.org/article/679201c6f1db448ba7559bf7d11b7abf
Autor:
Ali Tavakoli Pirzaman MD, Pouyan Ebrahimi MD, Amir Hossein Hasanpour MD, Mahdi Shakeri MD, Bahareh Babajani MS, Zahra Pourali Ganji MS, Hedye Babaei MD, Amirhossein Rahmati MS, Rezvan Hosseinzadeh MD, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 22 (2023)
Multiple myeloma (MM) produces clonal plasma cells and aberrant monoclonal antibody accumulation in patients’ bone marrow (BM). Around 1% of all cancers and 13% of hematological malignancies are caused by MM, making it one of the most common types
Externí odkaz:
https://doaj.org/article/0adaea8412f243719566c49e425bcb88
Publikováno v:
Drug Week; 11/3/2023, p1334-1334, 1p